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Abstract: Despite advances in immunosuppressive therapy, long-term renal-transplantation 
outcomes have not significantly improved over the last decade. The nephrotoxicity of calcineurin 
inhibitors (CNIs) is an important cause of chronic allograft nephropathy (CAN), the major 
driver of long-term graft loss. Everolimus is a proliferation signal inhibitor with a mechanism of 
action that is distinct from CNIs. The efficacy and tolerability of everolimus in renal-transplant 
recipients have been established in a wide range of clinical trials. Importantly, synergism 
between everolimus and the CNI cyclosporine (CsA) permits CsA dose reduction, enabling 
nephrotoxicity to be minimized without compromising efficacy. Currently, everolimus is being 
investigated in regimens where reduced exposure CNIs are used from the initial post-transplant 
period to improve renal function and prevent CAN. By inhibiting the proliferation of smooth 
muscle cells, everolimus may itself delay the progression or development of CAN. Although 
everolimus is associated with specific side effects, these can generally be managed. By targeting 
the main causes of short- and long-term graft loss, everolimus has a key role to play in renal 
transplantation, which is being explored further in a number of ongoing Phase III–IV trials.
Keywords: calcineurin inhibitors, chronic allograft nephropathy, cyclosporine, everolimus, 
renal function, renal transplantation
Introduction
Although advances in immunosuppressive therapy have improved the control of acute 
allograft rejection, long-term renal-transplantation outcomes have not significantly 
improved over the last decade.1 In renal-transplant patients, chronic allograft 
nephropathy (CAN; specifically interstitial fibrosis and tubular atrophy) is the main 
cause of graft failure. A number of factors have been implicated in the development 
of CAN, including donor age, acute rejection, vascular remodeling and calcineurin 
inhibitor (CNI)-induced nephrotoxicity.2 The CNIs cyclosporine (CsA) and tacrolimus 
have been the cornerstone of immunosuppressive therapy for many years, due to 
their efficacy in preventing acute rejection. However, CNIs have nephrotoxic side 
effects that can directly contribute to renal dysfunction and compromise long-term 
outcomes.3 Consequently, there has been strong interest in developing immunosup-
pressive regimens that maintain efficacy for the prevention of acute rejection, whilst 
minimizing risk factors for chronic allograft dysfunction and late graft loss.
Everolimus (Certican®; Novartis Pharma AG, Basel, Switzerland) is a proliferation 
signal inhibitor (PSI) with potent immunosuppressant effects.4 In the setting of renal 
transplantation, everolimus has displayed comparable efficacy to mycophenolate 
mofetil (MMF) when used with corticosteroids and standard-dose CsA for prevention International Journal of Nephrology and Renovascular Disease 2009:2 10
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of acute rejection.5,6 Moreover, Phase III studies in de novo 
renal-transplant patients have shown that everolimus allows 
for the early halving of CNI treatment whilst maintaining 
renal function, compared with full-dose CsA studies.7
In addition to its immunosuppressive efficacy, everolimus 
possesses other desirable attributes.4 For example, the 
antiproliferative mechanism of action of everolimus may 
help to prevent the main causes of long-term graft loss by 
inhibiting the underlying processes that contribute to chronic 
allograft dysfunction.
This review will summarize the clinical trial data for 
everolimus and its role in renal transplantation.
Everolimus in renal transplantation – 
efficacy
Mechanism of action
Everolimus belongs to a class of immunosuppressive agents, 
the PSIs (also known as mammalian target of rapamycin 
[mTOR] inhibitors), that inhibit the progression of T cells 
from G1 into the S phase of the cell cycle.8 By interfering 
with DNA replication at an early stage, PSIs exert an 
antiproliferative effect. The immunosuppressive action of 
everolimus has been demonstrated in preclinical studies 
in animal models of renal transplantation.9 Importantly, 
everolimus has a mechanism of action that is distinct 
from CNIs.3 Whereas CNIs prevent T-cell proliferation by 
blocking transcriptional activation of early T-cell-specific 
genes, inhibiting the production of T-cell growth factors 
(eg, IL-2), everolimus acts on a later stage of the T-cell 
response, by blocking the transduction of signals generated 
by such growth factors.4 A synergistic immunosuppressive 
effect has been demonstrated between everolimus and 
CsA in preclinical studies, which could be due to their 
complementary modes of action.10 These studies showed 
that, when used concomitantly, the equivalent efficacy of 
either agent alone could be achieved using 10% to 20% of 
the everolimus dose and 20% to 40% of the CsA dose,10 
providing a rationale for investigating whether everolimus 
could allow CsA dose reduction in patients receiving organ 
transplants.
Since everolimus inhibits growth factor-driven cell 
proliferation in general, its antiproliferative effects are not 
limited to the immune system.4 PSIs have been shown to 
inhibit smooth muscle cell proliferation and prevent vascular 
remodeling.11,12 Animal studies have demonstrated that the 
antiproliferative effects of everolimus reduce long-term 
graft-specific histological changes, delaying the progres-
sion of CAN, even when already at an advanced stage.13 
Therefore, the mechanism of action of everolimus appears 
to target the key cause of CAN.
Clinical efficacy studies
everolimus versus MMF with full-dose CsA
Two similarly designed Phase III studies (B201 and B251) 
compared the efficacy of everolimus versus MMF in de novo 
renal-transplant recipients (Table 1).5,6 Both were 36-month, 
parallel-group studies in which patients were randomized to 
fixed everolimus doses (1.5 or 3 mg/day) or MMF (2 g/day) 
as part of a triple immunosuppressive therapy regimen with 
full-dose CsA and corticosteroids.5,6 Treatment was blinded 
for the first year, followed by 2 years of open-label therapy. 
The primary endpoint was efficacy failure, a composite 
endpoint defined as the incidence of biopsy-proven acute 
refection (BPAR), graft loss, death, or loss to follow-up. In 
both studies, incidences of composite efficacy failure were 
similar between the MMF and everolimus 1.5 or 3.0 mg/day 
cohorts, with therapeutic equivalence maintained over 
36 months.5,6 In study B201, the incidence of graft loss at 
36 months was higher in the everolimus 3 mg/day group 
(16.7%) compared with the everolimus 1.5 mg/day group 
(7.2%, p = 0.0048) and the MMF group (10.7%, p = 0.1067).6 
In Study B251, the rate of antibody-treated acute rejection 
was significantly lower with everolimus 1.5 mg than with 
MMF at 12 months (7.8% vs 16.3%; p = 0.01) and at 
36 months (9.8% vs 18.4%; p = 0.014).5
Subsequent analysis of data from these studies 
demonstrated that patients with everolimus trough blood 
levels 3 ng/mL had a significantly reduced incidence of 
BPAR after 6 months of treatment, compared with those 
with trough blood levels 3 ng/mL (p  0.0001).14 In 
addition, patients receiving everolimus had higher mean 
serum creatinine levels than those receiving MMF.15 After 
12 months, protocol amendments were introduced, permitting 
lower CsA trough levels (50 to 75 ng/mL) in the everolimus 
groups, provided that everolimus blood trough levels were 
maintained above 3 ng/mL. After the protocol amend-
ments, mean serum creatinine levels decreased slightly, or 
remained stable, with no increase in BPAR.15 The finding that 
everolimus trough blood levels 3 ng/mL were necessary 
to gain the most clinical benefit highlighted that therapeutic 
drug monitoring might be useful in optimizing dosing for 
patients receiving everolimus and CsA.
everolimus with full- or reduced-exposure CNIs
CNI therapy is associated with nephrotoxicity, which can 
complicate otherwise successful therapy.16 Therefore, International Journal of Nephrology and Renovascular Disease 2009:2 11
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exploring drug combinations that allow for a reduction in 
CNI exposure might help to improve long-term outcomes.
Study B156 was a Phase II, 3-year, multicenter, 
randomized, open-label, parallel-group, CsA dose-finding 
study of everolimus in de novo renal-transplant recipients 
(Table 1).17 After transplantation, patients were randomized 
to either full-dose (trough blood level 125 to 250 ng/mL 
from 3 to 36 months) or reduced-dose (trough blood level 
50 to 100 ng/mL from 3 to 36 months) CsA, in addition 
to identical dose regimens of everolimus (3 mg/day), 
basiliximab (20 mg prior to transplantation and on Day 4) 
and corticosteroids.17 Following a protocol amendment, CsA 
dosing was adjusted to achieve trough blood levels of 50 to 
75 ng/mL and everolimus dosing was adjusted to ensure 
trough blood levels 3 ng/mL in all patients continuing 
treatment from 12 months onwards.17 The incidence 
of efficacy failure (BPAR, graft loss, death, or loss to 
follow-up) was significantly lower in the reduced-dose CsA 
group compared with the full-dose CsA group at 6 months 
(p = 0.046), 12 months (p = 0.012) and 36 months (p = 0.032), 
mainly as a result of the lower incidence of BPAR in the 
reduced-dose CsA group, compared with the full-dose group 
(3.4% vs 15.1% at 6 months; 6.9% vs 17.0% at 12 months; 
12.1% vs 18.9% at 36 months).17 In addition, mean serum 
creatinine levels were numerically lower in patients receiving 
reduced-dose CsA compared with full-dose CsA, and mean 
creatinine clearance rates were significantly higher in 
reduced-dose versus full-dose patients at 6 months (p = 0.009) 
and 12 months (p = 0.007).17 Following transition to the 
amended protocol after 12 months, mean serum creatinine 
levels fell in the full-dose CsA group, whilst mean serum 
creatinine and creatinine clearance values remained stable in 
the reduced-dose CsA group, reflecting the smaller reduction 
in CsA dose in these patients.17 Study B156 therefore demon-
strated that using everolimus with reduced-dose CsA resulted 
in preserved renal function without loss of efficacy, when 
compared with standard-dose CsA regimens.
Similar results were found with low-exposure tacrolimus 
and everolimus in Study US09, which was a prospective, 
6-month, multicenter, open-label, exploratory study. De novo 
renal-transplant recipients (n = 92) were randomized to evero-
limus, steroids and basiliximab with low or standard tacro-
limus exposure (Table 1).18 Lower tacrolimus exposure was 
not associated with loss of efficacy compared with a standard 
tacrolimus regimen, with BPAR occurring in 14% of patients 
in both the low and standard tacrolimus exposure groups at 
6 months. Moreover, there were no significant differences 
in renal function between groups at 6 months: mean serum 
creatinine levels were 112 ± 31 and 127 ± 50 µmol/L, and 
mean estimated glomerular filtration rates (GFRs) were 
75.3 ± 16.6 and 72.5 ± 15.2 mL/min, in the low and standard 
tacrolimus exposure groups, respectively.18 Overall, the 
study found that treatment with everolimus, in combination 
with low-exposure tacrolimus, steroids and basiliximab, was 
effective and well tolerated, resulting in good efficacy with 
excellent renal function at 6 months.18
Given that clinical data are lacking concerning 
therapeutic action and systemic exposure of a combined 
regimen of tacrolimus and everolimus in renal transplan-
tation, EVEROTAC, an investigator-driven, prospective, 
open-label, randomized Phase II pharmacokinetic (PK) 
study was undertaken in five Spanish centers randomly 
comparing two fixed everolimus dosages (0.75 mg bid, 
Group A, or 1.5 mg bid, Group B) in combination with 
tacrolimus (Pascual unpublished data). Antibody induction 
was not permitted and all patients received steroid therapy. 
Complete 12-hour PK curves of both drugs (high perfor-
mance liquid chromatography) were performed at Days 4, 
14 and 42 post-transplant. After Day 42, everolimus trough 
levels were adjusted to 3 to 8 ng/mL and tacrolimus to 
5 to 8 ng/mL. Higher tacrolimus trough blood levels were 
observed with everolimus dose of 0.75 mg bid. Accordingly, 
the exposure to tacrolimus was lower in the group receiving 
3 mg/day everolimus despite this combination requiring 
higher tacrolimus doses to maintain target concentrations. 
Everolimus minimum concentration (Cmin), maximum 
concentration (Cmax) and area under the curve (AUC) 
were very low with the initial dose of 0.75 mg bid when 
combined with tacrolimus and everolimus 1.5 mg bid seems 
to be the minimal initial advisable dose for Phase III trials. 
Higher doses would probably be needed for tacrolimus 
minimization strategies, as 3 mg/day appears insufficient to 
achieve 3 ng/mL during the first 2 weeks. Acute rejection 
incidence was 17%, good graft function was consistently 
achieved, wound healing was uneventful in all patients and 
lymphocele was diagnosed in only two cases (6%) (Pascual, 
unpublished data).
everolimus with reduced-exposure CsA
A2306 and A2307 were similarly designed Phase III, 1-year, 
parallel-group studies in which de novo renal-transplant 
patients were randomized to everolimus at an initial dose of 
1.5 or 3 mg/day (with subsequent dosing adjusted to maintain 
trough levels of 3 ng/mL for both groups), in combination 
with reduced-exposure CsA and steroids; patients in A2307 
also received induction therapy with basiliximab on the day of International Journal of Nephrology and Renovascular Disease 2009:2 13
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transplantation and after 4 days (Table 1).7 In Study A2306, 
CsA C2 (the 2-hour post-dose blood CsA concentration) 
target ranges were 1000 to 1400 ng/mL for Weeks 0 to 4, 
700 to 900 ng/mL for Weeks 5 to 8, 550 to 650 ng/mL for 
Weeks 9 to 12 and 350 to 450 ng/mL thereafter, but in 
Study A2307, the ranges were lower, owing to the use of 
basiliximab induction therapy: 500 to 700 ng/mL for Weeks 
0 to 8 and 350 to 450 ng/mL thereafter.7 The primary efficacy 
endpoint in both studies was renal function at 12 months. 
Secondary endpoints included the incidence of efficacy 
failure and its individual components at 12 months. Serum 
creatinine levels were stable from Month 2 or 3 onwards. 
When data from Study A2306 were compared with data from 
the B251 and B201 studies, concentration-controlled evero-
limus with reduced-exposure CsA was shown to result in an 
improvement in serum creatinine, creatinine clearance and 
GFR, compared with everolimus plus full-exposure CsA.7,14 
There were no significant differences between the everolimus 
1.5 and 3 mg/day groups in either study for any efficacy 
parameter, and the incidences of efficacy failure and BPAR 
were comparable to those observed in the B251 and B201 
studies.7 However, BPAR occurred more frequently with 
everolimus 1.5 mg/day in Study A2306 (25.0%) than in Study 
A2307 (13.7%), suggesting that anti-IL-2 receptor induction 
therapy is probably beneficial in reducing the risk of early 
BPAR when used with a lower dose of everolimus.7 Impor-
tantly, a comparison of data from Studies B201 (full-exposure 
CsA) and A2306 (reduced-exposure CsA) demonstrated 
that CsA blood levels can be reduced by at least 57% at 
12 months when used in combination with everolimus, with-
out adversely affecting either efficacy or safety.19 Consistent 
with data from studies B201 and B251, in which full-dose 
CsA was used,14 a post hoc analysis of data from Study A2306 
demonstrated that optimal efficacy and safety are achieved 
in patients receiving reduced-exposure CsA if everolimus 
trough blood levels are between 3 and 8 ng/mL.20 Ongoing 
studies are continuing to investigate the use of therapeutic 
drug monitoring to optimize everolimus levels in combination 
with reduced-exposure CsA.21–26
CNI elimination
The use of CNIs during the initial post-transplant period to 
prevent acute rejection and the subsequent elimination of 
CNIs from the treatment regimen may provide a means of 
preventing long-term nephrotoxicity.
The CENTRAL (CErtican Nordic Trial in RenAL 
transplantation) study evaluated whether early conversion 
to everolimus from CsA might improve long-term renal 
function and slow down the progression of CAN (Table 1).27 
In this single-center pilot study, 20 renal-transplant 
patients without prior rejection were converted from CsA 
to everolimus at Week 7 post-transplantation. All patients 
received basiliximab induction therapy with maintenance 
enteric-coated mycophenolate sodium (EC-MPS) and 
corticosteroids. Patients were monitored for 7 weeks, with 
a follow-up visit after 6 months.27 After conversion to 
everolimus and CsA elimination, calculated GFR improved 
significantly, from 51 ± 11 mL/min at the time of conversion 
to 58 ± 12 mL/min at Week 7 post-conversion and 
57 ± 17 mL/min at the 6-month follow-up visit (p = 0.001).27 
BPAR occurred in 3/20 (15.0%) patients during the 7 weeks 
post-conversion, but all episodes were mild and reversible, 
with subsequent recovery of renal function.27 In this pilot 
study, abrupt conversion from CsA to everolimus at Week 
7 post-transplant was well tolerated. Consequently the trial 
has been extended and is currently ongoing with planned 
enrollment of 300 patients and a follow-up of 3 years.
Additional benefits and clinical 
considerations
Multifaceted benefits
Antiproliferative effects
As described earlier, the antiproliferative effects of evero-
limus are not limited to the immune system.4 PSIs have 
been shown to inhibit smooth muscle cell proliferation and 
prevent vascular remodeling. This attribute may represent 
an additional benefit of everolimus as these proliferative 
processes are implicated in the development of CAN in 
renal-transplant recipients and cardiac allograft vasculopathy 
in cardiac-transplant recipients, which are key causes of 
allograft dysfunction11,12 Furthermore, animal studies have 
demonstrated that the antiproliferative effects of everolimus 
reduce long-term graft-specific histological changes, delaying 
the progression of CAN, even when already at an advanced 
stage.13 Studies of sirolimus and everolimus drug-eluting 
stents further support the ability of this class of drugs to 
inhibit pathological vascular remodeling.28,29 Taken together, 
these data suggest that the mechanism of action of everolimus 
appears to target the key cause of CAN.
Reduced CMv infection
A number of other factors aside from vascular remodelling 
have also been implicated in the development of CAN, 
including acute rejection episodes, CNI-induced neph-
rotoxicity, and complications of immunodeficiency such 
as opportunistic CMV infection.30 CMV is a leading International Journal of Nephrology and Renovascular Disease 2009:2 14
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cause of infectious complications in patients who have 
undergone solid organ transplantation. CMV infection is 
associated with allograft rejection, decreased graft and 
patient survival, and predisposition to malignancies.31 In 
the B201 study, the incidence of viral infection, particularly 
CMV infection, was significantly higher after treatment 
with MMF compared with everolimus.6 Similarly, earlier 
studies have suggested a reduced CMV infection rate with 
sirolimus.32
Anti-neoplastic effects
PSIs have been associated with anti-neoplastic effects 
as a result of their inhibition of cellular signaling path-
ways involved in critical functions such as cell division, 
T-cell activation, invasion and growth factor production.33 
A lower incidence of malignancies has been observed in 
patients receiving PSIs in clinical trials, compared with 
those receiving CNI-based immunosuppression.33 In renal 
carcinoma, everolimus has been shown to significantly 
prolong progression-free survival after failure of the approved 
therapies sunitinib or sorafenib in patients with advanced 
renal cell carcinoma and is currently being investigated in 
multiple tumor types.34
Adverse events
Renal-transplant recipients frequently experience adverse 
events as a result of surgery, immunosuppressant side effects 
and over-immunosuppression. The adverse events most 
frequently associated with everolimus treatment are similar 
to those associated with other immunosuppressive therapies, 
but PSIs, as a class, are associated with a number of specific 
adverse events.
Proteinuria
Many studies have confirmed that patients with CAN and, 
to a certain extent, patients without pre-existing CAN, are at 
risk of high-range urinary protein excretion after conversion 
to sirolimus.35,36 Moreover, proteinuria may occur in patients 
who receive de novo sirolimus.37 Less data are available about 
everolimus, but in the A2306 and A2307 studies, conducted 
in de novo renal-transplant recipients, proteinuria (determined 
by a spot urine protein/creatinine ratio) was detected in 5% 
of patients.38 The onset of abundant urinary protein excretion 
is of importance because proteinuria is a marker for the risk 
of progressive decline in renal function39 and is an important 
predictor of renal dysfunction following conversion from a 
CNI- to a PSI-based regimen.40 However, the mechanisms of 
PSI-induced proteinuria continues to be debated.41
Patients with pre-existing proteinuria at levels 800 mg/day 
should not undergo CNI elimination with conversion to 
a PSI.40 Angiotensin-converting enzyme inhibitors and 
angiotensin II receptor blockers may be used for the 
management of both hypertension and proteinuria in patients 
receiving everolimus.39,42 If massive proteinuria occurs after 
conversion, (re)introduction of CNI may partially reverse 
urinary protein excretion and seems a reasonable option.41
Dyslipidemia
Dyslipidemia is common in solid organ transplant recipients. 
PSIs have been linked to hyperlipidemia, with increased 
serum cholesterol and triglyceride levels occurring in 30% 
to 50% of patients.35,43
In renal-transplant recipients, sirolimus induces 
dose-dependent hyperlipidemia, including hypertriglyceri-
demia, increased low-density lipoprotein (LDL)-cholesterol 
and increased apolipoprotein B-100 and apolipoprotein C-III 
circulating levels. A similar increase in serum cholesterol and 
triglyceride levels has also been reported in renal transplant 
recipients receiving everolimus.44 However, when compared 
with MMF in de novo cardiac transplantation, everolimus 
did not induce clinically meaningful changes in triglyceride, 
LDL-cholesterol, or high-density lipoprotein-cholesterol 
levels.45 Dyslipidemia should be managed in accordance 
with guidelines, using lifestyle changes and drug therapy 
(eg, statins, fibrates).46 A crossover study conducted in 
healthy individuals found that single-dose administrations 
of everolimus with either atorvastatin or pravastatin did not 
influence the pharmacokinetics of everolimus or the statins 
to a clinically relevant extent.47
Hypercholesterolemia and hypertriglyceridemia are major 
risk factors for atherosclerosis and associated cardiovascular 
disease. Recent pre-clinical studies with sirolimus have 
demonstrated protection from atheroma progression in 
hyperlipidemic apolipoprotein E-deficient mice.48–50 As 
this may be a class effect of PSIs, studies are required to 
investigate if everolimus has any beneficial effects on the 
development on atherosclerosis.44
wound healing
Due to the antiproliferative action of PSIs, concerns have been 
raised over possible effects on tissue-regeneration processes. 
For example, the antiproliferative action of everolimus can 
reduce the healing of lymphatic channels that are divided 
during transplant surgery, which may lead to lymphatic 
leakage and the formation of a lymphocele.51 The potential 
impact on wound healing is most relevant in the immediate International Journal of Nephrology and Renovascular Disease 2009:2 15
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post-transplant period. Increased incidence of wound-healing 
complications associated with sirolimus treatment has 
been observed in renal transplantation.52 However, data 
pooled from the B201, B251, A2306 and A2307 everoli-
mus studies showed that the overall incidence and severity 
of wound-healing-associated complications following 
renal transplantation were comparable for MMF- and 
everolimus-based immunosuppressive regimens.53
edema
Limb edema and bilateral eyelid edema have been observed in 
transplant recipients receiving sirolimus and everolimus.36,51,54 
Although edema appears to be a class effect, in a study of 
56 cardiac-transplant patients undergoing CNI reduction 
or elimination, fewer patients experienced edema with 
everolimus (14.3%) than with sirolimus (64.3%; p = 0.001).55 
When edema does occur with everolimus treatment, dose 
reduction may be required, but it is generally still possible to 
maintain everolimus trough blood levels within the optimal 
therapeutic window (3 to 8 ng/mL).51
Pharmacokinetics: safety considerations
Although everolimus and sirolimus are PSIs with similar 
chemical structures (everolimus is a derivative of rapamycin 
bearing a hydroxyethyl chain at position 40), there are 
pharmacokinetic and pharmacodynamic differences between 
the molecules.15 For example, the half-life of everolimus 
(28 hours) is shorter than that of sirolimus (62 hours). 
Consequently steady-state is achieved more quickly with 
everolimus (4 days) than with sirolimus (6 days), due to 
differences in their treatment regimens.35 These differences 
may explain certain variations in the safety profiles of the 
two agents. For example, sirolimus has been associated with 
the development of pneumonitis following renal transplanta-
tion,56–58 which may be a cause of pulmonary fibrosis in later 
stages of the disease. By contrast, no cases of pneumonitis 
have been reported in renal-transplant patients receiving 
everolimus with low-dose CsA. Indeed, there have been case 
reports of the successful resolution of sirolimus-associated 
pneumonitis following switching from sirolimus to 
everolimus in renal-transplant patients59 and recipients of 
other solid-organ transplants.60
Ongoing Phase III–IV studies  
with everolimus
A number of Phase III and IV studies are underway to inves-
tigate the use of everolimus in renal transplantation and these 
studies are described here and in Table 2.
De novo renal transplantation
The open-label Mycophenolate sodium vs Everolimus or 
Cyclosporine with Allograft Nephropathy as Outcome 
(MECANO) study is investigating an initial 6-month regimen 
of basiliximab, CsA, EC-MPS and prednisolone, followed 
by randomization to 18 months of treatment with either CsA 
plus prednisolone, EC-MPS plus prednisolone, or evero-
limus plus prednisolone (Table 2).61 The aim of the study 
is to achieve optimal immune suppression with maximal 
reduction of side effects, especially of vascular injury. The 
primary outcome is the degree of inflammation, fibrosis and 
arteriolar hyalinosis in renal biopsies taken 6 and 24 months 
post-transplantation.61
Immediate (de novo) versus delayed 
everolimus administration
Delaying the administration of everolimus in de novo 
renal-transplant patients allows a shift of the anti-proliferative 
effect at the early post-transplantation period. CALLISTO is 
a multicenter, open-label, 12-month study, being conducted 
in patients who are deceased-donor renal-transplant recipi-
ents at risk of delayed graft function (DGF) (Table 2).62 
Patients are randomized to receive immediate everolimus 
(within 48 hours post-transplantation) or delayed everolimus 
after 4 weeks of EC-MPS treatment. All patients received 
anti-IL-2 receptor induction therapy and steroids. The 
primary endpoint is a composite of BPAR, graft loss, death, 
DGF, wound-healing events, or loss to follow-up.
CNI reduction or elimination
The use of therapeutic drug monitoring to optimize everolimus 
levels in combination with reduced-exposure CsA is being 
investigated further in the EVEREST (the upper target 
EVErolimus RandomisEd STudy) AIT02 study (Table 2).21 
This is a 6-month, multicenter, randomized, open-label study 
that is comparing two immunosuppressive regimens in de 
novo renal-transplant recipients: (a) higher everolimus target 
trough levels (C0 8 to 12 ng/mL) with very low-dose CsA 
(C2 600 ng/mL, tapered to 300 ng/mL at Month 3) and (b) 
standard everolimus target trough levels (C0 3 to 8 ng/mL) 
with low-dose CsA (C2 600 ng/mL, tapered to 500 ng/mL 
at Month 3). The primary objectives are to assess if the 
optimized new regimen with higher everolimus target 
trough levels and very low-dose CsA allows improvement in 
6-month creatinine clearance, in comparison with the standard 
everolimus regimen with low-dose CsA and to assess if the 
optimized new regimen is equally effective in preventing 
acute rejection, in comparison with the standard regimen.International Journal of Nephrology and Renovascular Disease 2009:2 16
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A2309 is a Phase III, 24-month, multicenter, randomized, 
open-label, non-inferiority study that will assess two doses 
of everolimus in combination with reduced-exposure CsA, 
compared with everolimus/EC-MPS administered with 
standard-exposure CsA (Table 2).22 A2309 has enrolled 833 
de novo renal-transplant patients at 83 centers worldwide. The 
primary objective of the study is to demonstrate that at least 
one of the everolimus treatment regimens is not inferior to the 
EC-MPS treatment regimen within 12 months of the initial 
dose of study medication with respect to primary efficacy 
failure, namely, the composite efficacy endpoint of treated 
BPAR episodes, graft loss, death or loss to follow-up.22
The ERIC study is a Spanish multicenter, randomized, 
open-label trial, to assess the effect of CNI withdrawal and 
early (at 3 months) introduction of everolimus on renal 
allograft function. The primary end-point will be calculated 
GFR at 2 years, and the first functional and histological 
results will be available in 2010.
The ZEUS A2418 study has been conducted in de novo 
renal-transplant patients in order to assess whether an 
EC-MPS plus everolimus regimen after CNI withdrawal was 
as safe and well-tolerated as the CsA plus EC-MPS regimen, 
and to determine whether this regimen resulted in improved 
renal function (Table 2).63 After induction therapy with 
basiliximab, all patients were treated with CsA, EC-MPS and 
corticosteroids for the first 4.5 months post-transplantation. 
Subsequently, patients were randomized 1:1 to either 
continue the current regimen of CsA and EC-MPS or to 
convert from CsA to everolimus. The primary objective 
of this trial was to show superiority of a CNI-free regimen 
with respect to the renal function at Month 12 post transplant 
assessed by GFR (Nankivell method) compared with the 
standard CNI-based regimen. The results have recently been 
submitted for publication.
Several other studies are investigating the use of everolimus 
treatment as a means of reducing or eliminating CNI therapy 
in de novo renal-transplant patients (Table 2).23–26,64,65
Maintenance renal-transplant recipients
The Assessment of everolimuS in addition to Calcineurin 
inhibitor reduction in the maintEnance of Renal TrAnsplant 
RecipIeNts (ASCERTAIN; A2413) study is a pivotal Phase 
IV trial that will assess the feasibility of CNI reduction/
elimination in maintenance renal-transplant patients suffer-
ing from renal impairment, and its impact on renal function 
and cardiovascular risk (Table 2).26 Patients are randomized 
to one of three parallel treatment groups: continuation of the 
current immunosuppressive regimen without everolimus; 
initiation of everolimus with discontinuation of CNI; or 
initiation of everolimus with reduction of CNI blood levels 
by 70% to 90%.26 The study is designed to evaluate whether 
the initiation of everolimus, together with the reduction 
or discontinuation of CNIs, will improve graft function 
and reduce the progression of CAN in maintenance renal-
transplant recipients.26 The development of atherosclerosis in 
the native arteries of the patients will also be explored.26
It is noteworthy that the effect of conversion from 
sirolimus to everolimus has been assessed in a 6-month, 
pilot study. Eleven maintenance renal-transplant patients 
receiving sirolimus, mycophenolic acid and corticosteroids 
without CNI therapy were converted to everolimus 8 mg/day 
(8 to 15 ng/mL).66 Mean GFR and mean renal-phosphate 
threshold remained stable throughout the study and no 
patient died, lost their graft or experienced BPAR after 
conversion.66
Conclusions
Evidence from clinical trials supports the efficacy and toler-
ability of everolimus in renal-transplant recipients. Notably, 
clinical trial data indicate that everolimus can facilitate CNI 
minimization/halving without compromising efficacy. By 
facilitating CNI minimization, and inhibiting smooth-muscle 
proliferation, everolimus may prevent the progression or 
development of CAN, hypotheses which are currently being 
investigated in the A2309,22 MECANO61 and ASCERTAIN 
(A2413)26 trials. There are several class-specific side effects 
associated with everolimus, but experience to date suggests 
that these can be managed. Everolimus has a key role to 
play in addressing current unmet needs in transplantation by 
targeting the causes of short and long-term graft loss. Ongo-
ing clinical studies will provide further information to refine 
the therapeutic role of everolimus in renal transplantation.
Acknowledgments
The author would like to thank Sarah Kaboutian, who 
provided medical-writing support on behalf of Novartis 
Pharma AG.
References
  1.  Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of 
improvement in renal allograft survival despite a marked decrease in 
acute rejection rates over the most recent era. Am J Transplant. 2004; 
4:378–383.
  2.  Chapman JR, O’Connell PJ, Nankivell BJ. Chronic renal allograft 
dysfunction. J Am Soc Nephrol. 2005;16:3015–3026.
  3.  Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor 
nephrotoxicity: longitudinal assessment by protocol histology. 
Transplantation. 2004;78:557–565.International Journal of Nephrology and Renovascular Disease 2009:2 20
Pascual Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  4.  Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin 
derivative: pharmacological properties in vitro and in vivo. 
Transplantation. 1997;64:36–42.
  5.  Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus 
mycophenolate mofetil in the prevention of rejection in de novo renal 
transplant recipients: a 3-year randomized, multicenter, phase III study. 
Transplantation. 2005;80:244–252.
  6.  Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety 
results from a study of everolimus versus mycophenolate mofetil in 
de novo renal transplant patients. Am J Transplant. 2005;5:2521–2530.
  7.  Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine 
dosing in renal transplant recipients: 6-month safety and efficacy results 
of two randomized studies. Am J Transplant. 2004;4:626–635.
  8.  Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. 
Annu Rev Immunol. 1996;14:483–510.
  9.  Viklicky O, Zou H, Muller V, et al. SDZ RAD prevents manifestation 
of chronic rejection in rat renal allografts. Transplantation. 2000;69: 
497–502.
10.  Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin 
derivative: synergism with cyclosporine. Transplantation. 1997;64:32–35.
11.  Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of 
rapamycin on growth factor-stimulated vascular smooth muscle cell 
DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-
derived growth factor action and antagonism of rapamycin by FK506. 
Transplantation. 1995;59:390–395.
12.  Schuurman HJ, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ 
RAD inhibits cold ischemia-induced vascular remodeling. Transplant 
Proc. 1999;31:1024–1025.
13.  Lutz J, Zou H, Liu S, Antus B, Heemann U. Apoptosis and treatment 
of chronic allograft nephropathy with everolimus. Transplantation. 
2003;76:508–515.
14.  Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitor-
ing for everolimus in kidney transplantation using 12-month exposure, 
efficacy, and safety data. Clin Transplant. 2005;19:145–152.
15.  Pascual J. Everolimus in clinical practice – renal transplantation. Nephrol 
Dial Transplant. 2006;21 Suppl 3:iii18–iii23.
16.  Bennett WM. The nephrotoxicity of immunosuppressive drugs. Clin 
Nephrol. 1995;43 Suppl 1:S3–S7.
17.  Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-expo-
sure cyclosporine in de novo renal-transplant recipients: a three-year 
phase II, randomized, multicenter, open-label study. Transplantation. 
2004;78:1332–1340.
18.  Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study 
of the use of everolimus with tacrolimus after renal transplantation 
demonstrates its effectiveness. Transplantation. 2008;85:821–826.
19.  Pascual J. Concentration-controlled everolimus (Certican): combination 
with reduced dose calcineurin inhibitors. Transplantation. 2005;79:
S76–S79.
20.  Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic con-
centration range defined from a prospective trial with reduced-exposure 
cyclosporine in de novo kidney transplantation. Ther Drug Monit. 
2004;26:499–505.
21.  EVEREST.ClinicalTrials.gov. Available from: http://clinicaltrials.gov/
ct2/show/NCT00170885?term=CRAD001AIT02&rank=1. Accessed 
05 January 2009.
22.  Study A2309.ClinicalTrials.gov. Available from: http://clinicaltrials.
gov/ct2/show/NCT00251004?term=crad001a2309&rank=1. Accessed 
05 January 2009.
23.  Study A2426.ClinicalTrials.gov. Available from: http://clinicaltrials.gov/
ct2/show/NCT00369161?term=CRAD001A2426&rank=1. Accessed 05 
January 2009.
24.  HERAKLES Study.ClinicalTrials.gov. Available from: http://www.
clinicaltrials.gov/ct2/show/NCT00514514?term=crad001ade13&rank=1. 
Accessed 05 January 2009.
25.  Study A2419.ClinicalTrials.gov. Available from: http://www.clini-
caltrials.gov/ct2/show/NCT00154284?term=crad001a2419&rank=1. 
Accessed 05 January 2009.
26.  Assessment of Everolimus in Addition to Calcineurin Inhibitor 
Reduction in the Maintenance of Renal Transplant Recipients 
(ASCERTAIN) study (A2413).ClinicalTrials.gov. Available from: 
http://www.clinicaltrials.gov/ct2/show/NCT00170846?term=crad001
a2413&rank=1. Accessed 05 January 2009.
27.  Holdaas H, Bentdal O, Pfeffer P, et al. Early, abrupt conversion of de 
novo renal transplant patients from cyclosporine to everolimus: results 
of a pilot study. Clin Transplant. 2008;22:366–371.
28.  Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison 
of a sirolimus-eluting stent with a standard stent for coronary revascu-
larization. N Engl J Med. 2002;346:1773–1780.
29.  Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from 
first human experience using everolimus-eluting stents with bioabsorb-
able polymer. Circulation. 2004;109:2168–2171.
30.  Nashan B. The role of Certican (everolimus, rad) in the many pathways 
of chronic rejection. Transplant Proc. 2001;33:3215–3220.
31.  Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in 
transplantation – challenging the status quo. Clin Transplant. 2007;21: 
149–158.
32.  Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus 
infection in solid organ transplant recipients treated with sirolimus: a pooled 
analysis of clinical trials. Transplant Proc. 2008;40:1407–1410.
33.  Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal 
inhibitors in post-transplant malignancies. Nephrol Dial Transplant. 
2007;22 Suppl 1:i11–i16.
34.  Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in 
advanced renal cell carcinoma: a double-blind, randomised, placebo-
controlled phase III trial. Lancet. 2008;372:449–456.
35.  Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal 
transplantation: a review of clinical trial data, current usage, and future 
directions. Transplant Rev. 2006;20:1–18.
36.  Kuypers DR. Benefit-risk assessment of sirolimus in renal transplanta-
tion. Drug Saf. 2005;28:153–181.
37.  Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in 
proteinuria and graft function in de novo sirolimus-based vs calcineurin 
inhibitor-based immunosuppression in live donor kidney transplanta-
tion. Transplantation. 2006;82:368–374.
38.  Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and 
efficacy of everolimus with reduced exposure cyclosporine in de novo 
renal transplant recipients. Transpl Int. 2007;20:27–36.
39.  Keane WF. Proteinuria: its clinical importance and role in progressive 
renal disease. Am J Kidney. Dis 2000;35:S97–S105.
40.  Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in 
conversion from calcineurin inhibitor to sirolimus in chronic allograft 
dysfunction. Am J Transplant. 2004;4:1869–1875.
41.  Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: 
mechanisms, significance, and management. Transplant Rev (Orlando). 
2008;22:125–130.
42.  Muirhead N, House A, Hollomby DJ, Jevnikar AM. Effect of valsartan 
on urinary protein excretion and renal function in patients with chronic 
renal allograft nephropathy. Transplant Proc. 2003;35:2412–2414.
43.  Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ 
transplantation. Drugs. 2007;67:369–391.
44.  Andres V, Castro C, Campistol JM. Potential role of proliferation signal 
inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial 
Transplant. 2006;21 Suppl 3:iii14–iii17.
45.  Magnani G, Vigano M, Maccherini M, et al. Everolimus- vs 
MMF-based immunosuppression: comparable lipid profiles at one 
year after cardiac transplantation [poster]. American Transplant 
Congress, Toronto, Canada, 30 May – 4 June. Am J Transplant. 2008; 
8(S2):347.
46.  Kasiske BL, de MA, Flechner SM, et al. Mammalian target of rapamycin 
inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 
2008;8:1384–1392.
47.  Kovarik JM, Hartmann S, Hubert M, et al. Pharmacokinetic and pharma-
codynamic assessments of HMG-CoA reductase inhibitors when coad-
ministered with everolimus. J Clin Pharmacol. 2002;42:222–228.International Journal of Nephrology and Renovascular Disease 2009:2
International Journal of Nephrology and Renovascular Disease
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nephrology-and-renovascular-disease-journal
The International Journal of Nephrology and Renovascular Disease is an 
international, peer-reviewed open-access journal focusing on the patho-
physiology of the kidney and vascular supply. Epidemiology, screening, 
diagnosis, and treatment interventions are covered as well as basic science, 
biochemical and immunological studies. The journal welcomes original 
research, clinical studies, reviews & evaluations, expert opinion and com-
mentary, case reports and extended reports. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
21
everolimus in renal transplantation Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
48.  Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the 
immunosuppressant sirolimus against aortic atherosclerosis in apo 
E-deficient mice. Am J Transplant. 2003;3:562–569.
49.  Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin 
attenuates atherosclerotic plaque progression in apolipoprotein E 
knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc 
Pharmacol. 2005;46:481–486.
50.  Waksman R, Pakala R, Burnett MS, et al. Oral rapamycin inhibits 
growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc 
Radiat Med. 2003;4:34–38.
51.  Pascual J, Marcen R, Ortuno J. Clinical experience with everolimus 
(Certican): optimizing dose and tolerability. Transplantation. 2005;79:
S80–S84.
52.  Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical 
wound complication rates with sirolimus immunosuppression after 
kidney transplantation: a matched-pair pilot study. Transplantation. 
2003;76:426–429.
53.  Margreiter R, Vitko S, Whelchel J, et al. Post-operative tissue regenera-
tion in renal transplantation: comparable outcome with everolimus or 
MMF. Transplantation Society XXII Annual Congress, August 10–14, 
Sydney, Australia. Transplantation. 2008;86(S2):188.
54.  Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in 
kidney transplant recipients. Transplantation. 2001;72:162–164.
55.  Moro JA, Almenar L, Martinez-Dolz L, et al. Tolerance profile of 
the proliferation signal inhibitors everolimus and sirolimus in heart 
transplantation. Transplant Proc. 2008;40:3034–3036.
56.  Champion L, Stern M, Israel-Biet D, et al. Brief communication: 
sirolimus-associated pneumonitis: 24 cases in renal transplant 
recipients. Ann Intern Med. 2006;144:505–509.
57.  Garrean S, Massad MG, Tshibaka M, et al. Sirolimus-associated 
interstitial pneumonitis in solid organ transplant recipients. Clin 
Transplant. 2005;19:698–703.
58.  Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced 
pneumonitis: three cases and a review of the literature. Am J Transplant. 
2004;4:137–139.
59.  Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-
induced pneumonitis after conversion to everolimus. Transplant Proc. 
2006;38:711–713.
60.  De SP, Petruccelli S, Precisi A, et al. Switch to everolimus for 
sirolimus-induced pneumonitis in a liver transplant recipient – not all 
proliferation signal inhibitors are the same: a case report. Transplant 
Proc. 2007;39:3500–3501.
61.  Mycophenolate sodium vs Everolimus or Cyclosporine with Allograft 
Nephropathy as Outcome (MECANO) study. Netherlands Trial 
Register. Available from: http://www.trialregister.nl/trialreg/admin/
rctview.asp?TC=567. Accessed 05 January 2009.
62.  CALLISTO.ClinicalTrials.gov. Available from: http://clinicaltrials.gov/
ct2/show/NCT00154297?term=CRAD001A2420&rank=2. Accessed 
05 January 2009.
63.  ZEUS.ClinicalTrials.gov. Available from:http://clinicaltrials.gov/
ct2/show/NCT00154310?term=CRAD001A2418&rank=1. Accessed 
05 January 2009.
64.  Steroid Or Cyclosporine Removal After Transplantation using Everoli-
muS (SOCRATES) study (A2421).ClinicalTrials.gov. Available from: 
http://www.clinicaltrials.gov/ct2/show/NCT00371826?term=crad001a
2421&rank=1. Accessed 05 January 2009.
65.  Study A2423.ClinicalTrials.gov. Available from: http://www.
clinicaltrials.gov/ct2/show/NCT00170807?term=crad001a2423&rank=1. 
Accessed 05 January 2009.
66.  Kamar N, Jaafar A, Esposito L, et al. Conversion from sirolimus 
to everolimus in maintenance renal transplant recipients within a 
calcineurin inhibitor-free regimen: results of a 6-month pilot study. 
Clin Nephrol. 2008;70:118–125.